JNK1 inhibitor BMS-986360

{
  "id": "MLC-T-ONC-014625",
  "term": "JNK1 inhibitor BMS-986360",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, second-generation inhibitor of c-Jun N-terminal kinase 1 (JNK-1; JNK1; mitogen-activated protein kinase 8; MAPK8), with potential antineoplastic, anti-inflammatory and anti-fibrotic activities. Upon oral administration, JNK1 inhibitor BMS-986360 selectively targets, binds to and inhibits the activity of JNK1. Inhibition of JNK1-mediated mitogen-activated protein kinase (MAPK)-signaling pathways induces cell cycle arrest and apoptosis, decreases migration and invasion, and inhibits proliferation in JNK1-overexpressing cancer cells. Inhibition of JNK1-mediated pathways may also decrease fibrosis. JNK1, a member of the MAPK family and stress-activated protein, plays a role in the MAPK-mediated signaling pathway. It is often dysregulated in cancer cells and fibrosis.",
  "synonyms": [
    "c-Jun N-terminal kinase inhibitor BMS-986360",
    "JNK1 inhibitor CC-90001",
    "mitogen-activated protein kinase 8 inhibitor BMS-986360"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/jnk1-inhibitor-bms-986360/"
}